About Jade Biosciences Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate JADE101 targets the cytokine APRIL and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201 an afucosylated anti-BAFF-R monoclonal antibody as well as JADE301 an undisclosed antibody candidate both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics an antibody discovery engine founded by Fairmount. For more information visit JadeBiosciences.com and follow the Company on LinkedIn Role Overview The Associate Director Clinical Site Budgets & Payments will architect and lead the company’s global approach to clinical … Sign In to View